Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2007-01-09
2007-01-09
Habte, Kahsay (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C544S058200
Reexamination Certificate
active
10766122
ABSTRACT:
The present invention relates to a new crystalline modification of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(1,1-dioxo-1λ6-thiomorpholin-4-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide characterized by the following X-ray diffraction pattern obtained with a CuKα, radiation at 2θ (2Theta)=4.5, 6.4, 7.5, 7.7, 8.0, 8.2, 10.0, 10.2, 10.9, 11.1, 12.9, 13.4, 14.0, 14.5, 15.1, 15.6, 16.2, 16.5, 17.3, 17.5, 18.0, 18.9, 19.3, 19.5, 19.9, 20.1, 20.6, 21.0, 21.4, 22.7, 23.1 and 23.6 and an infrared spectrum having sharp bands at 2925, 2854, 1637, 1604, 1484, 1395, 1375, 1285, 1230, 1172, 1125, 1082, 999, 943, 893, 868, 860, 782, 705, 684 cm−1, and wherein the extrapolated melting point (DSC) is 137.2° C.
REFERENCES:
patent: 5972938 (1999-10-01), Rupniak et al.
patent: 2003/0004157 (2003-01-01), Buser et al.
patent: 1 035 115 (2000-09-01), None
patent: 2347422 (2002-09-01), None
patent: WO 95/16679 (1995-06-01), None
patent: WO 95/18124 (1995-07-01), None
patent: WO 95/23798 (1995-09-01), None
patent: WO 02/085458 (2002-10-01), None
Navari, et al.,New England J. of Medicine, vol. 340, pp. 190-195 (1999).
Maggi et al.,J. Auton. Pharmacol., vol. 13, pp. 23-93 (1993).
Kramer et al.,Science, vol. 281, pp. 1640-1645 (1998).
Longmore et al.,Can. J. Physiol. Pharmacol., vol. 75, pp. 612-621 (1997).
Barker,Reviews in Neurosciences, vol. 7, pp. 187-214 (1996).
Quartara et al.,Neuropeptides., vol. 32(1), pp. 1-49 (1998).
Doi et al.,Eur. J. of Pharmacology., vol. 383(3), pp. 297-303 (1999).
Palma et al.,Life Sciences., vol. 67(9), pp. 985-1001 (2000).
Mutra et al.,Nature., vol. 405, pp. 180-183 (2000).
Stout et al., Neurokinin 1 Receptor Antagonists as Potential Antidepressants,Annu. Rev. Pharmacol. Toxicol.vol. 41, pp. 877-906 (2001).
Rupniak, N., Elucidating the antidepressant actions of substance P (NK1receptor) antagonists,Current Opinion in Investigational Drugs, vol. 3(2), pp. 257-261 (2002).
Humphrey, J., Medicinal Chemistry of Selective Neurokinin-1 Antagonists,Current Topics in Medicinal Chemistry, vol. 3, pp. 1423-1435 (2003).
Hoffmann Torsten
Hoffmann-Emery Fabienne
Nick Sonja
Schwitter Urs
Waldmeier Pius
Habte Kahsay
Hoffmann-La Roche Inc.
Johnston George W.
Prior Kimberly J.
Rocha-Tramaloni Patricia S.
LandOfFree
Crystalline modifications of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Crystalline modifications of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Crystalline modifications of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3782131